Biogen Pledges Aduhelm Confirmatory Data By 2026, Renewing Spotlight On FDA’s Lengthy Original Plan

 
• By Jessica Merrill

Biogen's update on the timeline for running a confirmatory study of the Alzheimer's treatment is much faster than the nine years required by US FDA under the accelerated approval.

Biogen
Biogen plans to begin an Aduhelm confirmatory study in May • Source: Alamy

More from Post-Marketing Regulation & Studies

More from Product Reviews